Suppr超能文献

给予健康志愿者噻氯匹定对全血中血小板功能的影响。

Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood.

作者信息

Heptinstall S, May J A, Glenn J R, Sanderson H M, Dickinson J P, Wilcox R G

机构信息

University Hospital, Queen's Medical Centre, Nottingham, U.K.

出版信息

Thromb Haemost. 1995 Nov;74(5):1310-5.

PMID:8607115
Abstract

Ticlopidine is thought to be a selective inhibitor of ADP-induced platelet function. Here we have investigated the effects of ticlopidine on platelet function in whole blood induced by ADP and by other platelet agonists. Whole blood was used because it was considered that ADP derived from red cells might act synergistically with other platelet agonists to enhance platelet responses, and that ticlopidine might interfere with this process. Measurements were performed using blood from 16 healthy volunteers before ticlopidine administration, after taking ticlopidine 250 mg daily for 10 days, after taking ticlopidine 250 mg twice daily for a further 10 days, and after 14 days off treatment. Ticlopidine proved to be a very effective inhibitor of the platelet aggregation induced by ADP; it was most effective in enhancing the reversibility of the aggregation response. The drug modestly but significantly reduced streptokinase, adrenaline, collagen, sodium arachidonate, PAF and U46619 - induced platelet aggregation. The drug significantly reduced the extent of the release reaction (14C-5HT release) induced by ADP, streptokinase, PAF, ristocetin and sodium arachidonate, and also reduced the extent of the synergistic 14C-5HT release induced by combinations of ADP and PAF, ADP and adrenaline and PAF and adrenaline. The various inhibitory effects of ticlopidine were evident after treatment with 250 mg daily but were more pronounced after 250 mg twice daily. All values had returned to normal after 14 days off treatment. Ticlopidine had no effect on serum thromboxane B2 production nor on several parameters of coagulation and fibrinolysis. We conclude that ticlopidine is an effective inhibitor of ADP-induced platelet aggregation and also the platelet aggregation and 14C-5HT release induced in whole blood by a number of platelet agonists and combinations of agonists. These latter effects are probably mainly via a selective effect on ADP. The inhibitory effects of the drug are dose-related.

摘要

噻氯匹定被认为是一种ADP诱导的血小板功能的选择性抑制剂。在此,我们研究了噻氯匹定对全血中由ADP和其他血小板激动剂诱导的血小板功能的影响。使用全血是因为认为来自红细胞的ADP可能与其他血小板激动剂协同作用以增强血小板反应,并且噻氯匹定可能会干扰这一过程。测量是使用16名健康志愿者的血液进行的,在服用噻氯匹定之前、每天服用250毫克噻氯匹定10天后、再连续10天每天服用250毫克噻氯匹定两次后以及停药14天后进行。结果证明噻氯匹定是ADP诱导的血小板聚集的非常有效的抑制剂;它在增强聚集反应的可逆性方面最为有效。该药物适度但显著地降低了链激酶、肾上腺素、胶原、花生四烯酸钠、PAF和U46619诱导的血小板聚集。该药物显著降低了由ADP、链激酶、PAF、瑞斯托霉素和花生四烯酸钠诱导的释放反应(14C - 5HT释放)的程度,并且还降低了由ADP和PAF、ADP和肾上腺素以及PAF和肾上腺素组合诱导的协同14C - 5HT释放的程度。噻氯匹定的各种抑制作用在每天服用250毫克后就很明显,但在每天服用250毫克两次后更为显著。停药14天后所有值均恢复正常。噻氯匹定对血清血栓素B2的产生以及凝血和纤维蛋白溶解的几个参数均无影响。我们得出结论,噻氯匹定是ADP诱导的血小板聚集以及全血中由多种血小板激动剂和激动剂组合诱导的血小板聚集和14C - 5HT释放的有效抑制剂。后一种作用可能主要是通过对ADP的选择性作用。该药物的抑制作用与剂量相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验